Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock

Rhea-AI Impact

(Very High)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Analysis in progress...

AI-generated analysis. Not financial advice.

News Market Reaction – LNAI

-2.62%

4 alerts

-2.62% News Effect

+15.2% Peak Tracked

-2.8% Trough Tracked

-$283K Valuation Impact

$10.52M Market Cap

24.88K Volume

On the day this news was published, LNAI declined 2.62%, reflecting a moderate negative market reaction. Argus tracked a peak move of +15.2% during that session. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $283K from the company's valuation, bringing the market cap to $10.52M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Expedited discovery motion date: May 18, 2026 Discovery request length: 18 pages Discovery request items: 21 items +4 more

7 metrics

Expedited discovery motion date May 18, 2026 Date Lunai filed Emergency Ex Parte Motion for expedited discovery

Discovery request length 18 pages Length of discovery request attached as exhibit to Motion

Discovery request items 21 items Number of items in Lunai’s discovery request

Complaint counts 3 counts Securities fraud, market manipulation, and wire fraud claims

Doe individual defendants Does 1–50 Range of unnamed individual defendants in Complaint

Doe corporate defendants Roe Corporations 1–50 Range of unnamed corporate defendants in Complaint

Doe LLC defendants XYZ LLCs 1–50 Range of unnamed LLC defendants in Complaint

Market Reality Check

Price: $2.45 Vol: Volume 2,076,166 is below...

low vol

$2.45 Last Close

Volume Volume 2,076,166 is below the 20-day average of 8,514,266, suggesting the 29.11% move came on relatively light trading. low

Technical Shares at $0.2901 are trading well below the $0.75 200-day moving average and about 82.52% under the $1.66 52-week high, despite being 91.74% above the $0.1513 52-week low.

Peers on Argus

No peers from the Biotechnology / Pharmaceutical Preparations group appeared in ...

No peers from the Biotechnology / Pharmaceutical Preparations group appeared in the momentum scan, indicating the 29.11% move in LNAI was stock-specific rather than part of a sector-wide rotation.

Historical Context

5 past events · Latest: May 20 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 20	Reverse stock split	Negative	-2.6%	Announced 1-for-8 reverse split to address Nasdaq minimum bid-price compliance.
May 04	IP acquisition financing	Positive	+1.5%	Completed $20M Series B preferred issuance to acquire CNS delivery and neurotherapeutic IP.
Apr 15	Rare disease LOI	Positive	-4.7%	Signed LOI with Geneial to build rare neurological disease cohorts for pharma deals.
Apr 07	Defense collaboration	Positive	+39.8%	Secured first revenue-generating, multi-year defense collaboration using AI chemical threat platform.
Mar 26	Strategic CNS deal	Positive	+22.9%	Executed $20M strategic transaction for BBB delivery platform and CNS Alzheimer’s assets.

Pattern Detected

LNAI has often reacted positively to strategic and collaboration news, while some partnership and corporate actions (like LOIs and reverse splits) have seen weaker or negative reactions.

Recent Company History

Over the last few months, Lunai reported several strategic steps, including a $20.0M CNS delivery acquisition on Mar 26, 2026 and a revenue-generating defense collaboration on Apr 7, 2026, which were followed by gains of 22.94% and 39.75%, respectively. An April LOI for rare-disease cohorts saw a -4.69% move, showing not all partnership news was rewarded. A reverse split announcement on May 20, 2026 coincided with a -2.64% reaction. Against this backdrop, the legal action over alleged naked short selling adds a new, litigation-focused catalyst.

Market Pulse Summary

This announcement centers on a federal court granting Lunai expedited discovery to identify alleged ...

Analysis

This announcement centers on a federal court granting Lunai expedited discovery to identify alleged “naked” short sellers, marking an escalation of its response to perceived trading abuses. Recent history shows the company combining strategic transactions, defense collaborations, and corporate actions to stabilize operations and Nasdaq compliance. The new lawsuit adds legal complexity alongside existing regulatory and financing considerations. Observers may focus on how discovery unfolds, the scope of alleged misconduct, and future operational milestones highlighted in prior updates.

Key Terms

naked short selling, securities fraud, market manipulation, section 10(b), +3 more

7 terms

naked short selling financial

"an alleged scheme involving 'naked short selling and manipulative trading intended to depress"

Naked short selling is selling shares you do not own and have not borrowed or reserved to deliver to the buyer, unlike ordinary short selling where the seller first borrows the shares. Think of it as promising to sell a car you haven’t secured from a lender or owner; if the seller can’t deliver, it can artificially increase the number of shares trading, push the price down, and raise risks for investors and for the company’s market stability.

securities fraud regulatory

"alleging securities fraud (stock manipulation) and intentional tort against "John Doe""

Securities fraud is the illegal act of lying to or misleading investors about the true value or prospects of stocks, bonds or other traded financial instruments — for example by making false statements, hiding key facts, trading on secret information, or artificially moving prices. It matters to investors because it can cause sudden losses, distort fair market prices and undermine trust in markets; think of it as someone rigging a scoreboard so others place bets on the wrong team.

market manipulation regulatory

"securities fraud (stock manipulation) and intentional tort against "John Doe""

Market manipulation is when individuals or groups deliberately distort the price or supply of a security by using deceptive or artificial tactics — for example spreading false information, placing fake orders, or coordinating trades to create a false appearance of demand. It matters to investors because it can make prices unreliable, hide real risk or value, and cause sudden losses when the manipulation stops, much like someone rigging an auction to make a bid look more valuable than it really is.

section 10(b) regulatory

"securities fraud under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5"

Section 10(b) is a provision of U.S. securities law that outlaws deceptive or manipulative practices in buying or selling stocks and other securities. It matters to investors because it provides a legal foundation for holding people accountable when false or misleading statements, hidden facts, or market manipulation distort prices—like a rule that makes sure everyone plays fair in a marketplace, helping protect the value of investors’ holdings and confidence in the market.

rule 10b-5 regulatory

"under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder"

A U.S. securities rule that makes it illegal to lie, omit important facts, or use deceptive practices when buying or selling stocks and other securities. Think of it as a sports referee rule that keeps the playing field fair: investors rely on truthful information to decide whether to buy or sell, and violations can lead to lawsuits, fines, or forced returns of profits, which can affect a company’s stock price and investor confidence.

wire fraud regulatory

"the intentional tort of wire fraud under 18 U.S.C. § 1343"

A federal crime involving using electronic communications—such as phone calls, email, text messages, or the internet—to carry out a deliberate scheme to cheat people or companies out of money or property. Think of it like someone tricking a person over the phone or by email into handing over cash or sensitive information. For investors, wire fraud allegations can mean legal penalties, unexpected costs, damaged reputation and sharp drops in a company’s stock value.

civil rico regulatory

"such egregious conduct cries out for amending the Complaint to allege civil RICO"

A civil RICO claim is a private lawsuit that lets investors or other parties sue a company or individuals for a sustained pattern of illegal conduct—such as fraud, bribery, extortion or other coordinated wrongdoing—that harms a business or its creditors. It matters to investors because a successful civil RICO case can bring large monetary awards, court orders to stop harmful activity, and serious reputational damage; think of it as a legal tool to unwind a long-running scheme and recover losses, like pulling a thread that unravels a damaged sweater and exposes underlying problems.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/22/2026 - 09:15 AM

WASHINGTON, May 22, 2026 /PRNewswire/ -- On Wednesday, May 20, 2026, a United States District Court Magistrate Judge in Delaware granted the Motion of Lunai Bioworks, Inc. (Nasdaq: LNAI) (Lunai) to conduct expedited discovery to identify the "John Doe" "naked" short sellers of Lunai common stock on the Nasdaq Stock Market in late 2025 and throughout the first half of 2026. Co-lead counsel, Jacob Frenkel, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from the 'naked' short sellers who have caused real market harm to Lunai and its shareholders."

The Court's Order granted Lunai's Emergency Ex Parte Motion for Leave to Engage in Expedited Limited Third-Party Discovery filed on Monday, May 18, 2026, after carefully reviewing the governing legal precedent and establishing that Lunai, through counsel, established "good cause" to permit discovery before the more typical timing under the Federal Rules of Civil Procedure. In finding "good cause," the Court made the threshold determination that Lunai "established a prima facie case for each essential element of the claim(s) in question." The Court recognized that Lunai demonstrated "[a] that it has no other way to identify the alleged wrongdoers, aside from obtaining the discovery at issue[,] or [b] that expedited discovery is necessary because evidence identifying the defendants may be otherwise destroyed[.]" The Court concluded that Lunai "made a prima facie showing for each element of at least Counts I and/or II of the three counts … via the detailed allegations it made regarding an alleged scheme involving 'naked short selling and manipulative trading intended to depress [Plaintiff's] stock price[.]'" Additionally, in recognizing the need to take discovery beginning with broker-dealers and custodians, the Court acknowledged that "this type of information is 'uniquely held by market infrastructure entities and market participants.'" Moreover, the Court pointed out that the "timing" of the trading anomalies and urgency and the "context" also were factors supporting granting the Motion.

Co-lead counsel, Sidney Liebesman, Senior Litigation Partner in Fox Rothschild's Delaware office, added: "The Court appreciated both the gravity and time sensitivity of the need to commence discovery. Our courts in Delaware understand the harms that can be perpetrated against quality corporations, and we look forward to pressing this case aggressively on behalf of Lunai."

Lunai, through its two law firm counsel, will be issuing discovery to the broker-dealers and custodians identifiable as having traded Lunai stock as the first layer of discovery. According to the Motion and the 18-page, 21-items discovery request attached as an exhibit to the Motion, Lunai will be seeking, among many things, the identity of all investors who took naked short positions, confirmation that the naked short sellers had violated the law by not borrowing the stock, information regarding the number of shares sold short and the specific naked short sale transactions, and trading blotters.

On Monday, May 11, 2026, national law firms Dickinson Wright and Fox Rothschild joined forces to file the lawsuit on behalf of their firms' client, Lunai, alleging securities fraud (stock manipulation) and intentional tort against "John Doe" "naked" short sellers of Lunai common stock on the Nasdaq Stock Market. The Complaint seeks compensatory damages, which could multiply if Lunai amends the Complaint to assert civil RICO claims. Frenkel, a former federal prosecutor and SEC Enforcement lawyer, added that "such egregious conduct cries out for amending the Complaint to allege civil RICO. A civil RICO judgment against naked short sellers should reverberate across the market, and the Court permitting us to push discovery only advances that goal."

Lunai, as set forth in the lawsuit, is an AI-driven platform for precision medicine that identifies targets for new therapeutics and biodefense countermeasures. The company also has developed a cancer immunotherapy for solid tumors. The Complaint tells the company's story for 2025 to the present -- referencing an April 2025 strategic merger, a May 2025 launch of an AI-powered precision neurology platform, a November 2025 announcement of the company's next-generation dendritic cell immunotherapy having achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models to mark a potential treatment, a March 2026 national initiative that uses artificial intelligence and cross-sector collaboration to accelerate the discovery and development of chemical countermeasures for emerging threats, an April 2026 deployment of an AI-powered platform for chemical threat assessment, and May 2026 intellectual property acquisitions that expanded Lunai's central nervous system platform.

The Complaint asserts three counts: (1) securities fraud under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder; (2) market manipulation under Section 9(a) of the Securities Exchange Act of 1934; and (3) the intentional tort of wire fraud under 18 U.S.C. § 1343. Lunai seeks compensatory and special damages, injunctive relief, prejudgment and post-judgment interest, and recovery of costs and reasonable attorneys' fees. The defendants are identified in the complaint as Does 1-50, Roe Corporations 1-50, and XYZ LLCs 1-50, pending discovery that will reveal their true identities. Dickinson Wright and Fox Rothschild intend to pursue expedited discovery to identify the defendants and seek emergency injunctive relief to halt the ongoing manipulative trading.

The Complaint in Lunai Bioworks, Inc. v. Does 1-50, Roe Corporations 1-50, and XYZ LLCs 1-50, 1:26-cv-00549-CFC (filed Monday, May 11, 2026) is on file in the United States District Court for the District of Delaware. Jacob Frenkel (Dickinson Wright, Washington, D.C.), and Sidney Liebesman (Fox Rothschild, Wilmington, Delaware) are co-lead counsel to Lunai, and Brian Yu (Dickinson Wright, Washington, D.C.) also is litigation counsel to Lunai.

About Lunai Bioworks, Inc.
Lunai Bioworks, Inc. is a Delaware corporation headquartered in Sacramento, California. Lunai is an AI-driven platform for precision medicine that identifies targets for new therapeutics and biodefense countermeasures. The company has developed a cancer immunotherapy for solid tumors and proprietary, patented technologies that transform complex biomedical data into predictive insights. Lunai's platforms include Augusta, an AI-powered precision neurology platform, and a portfolio focused on central nervous system disorders. The company also pursues federal government contracts in support of national security and biodefense applications through its AI platform.

About Fox Rothschild LLP
Fox Rothschild LLP is a law firm with approximately 1000 attorneys in 30 offices across major markets in the United States. Fox represents public and private companies, financial institutions, and individual clients in complex commercial litigation, securities law, intellectual property, corporate transactional matters, and related practice areas. Fox's Securities Litigation group has extensive experience representing issuers in federal court and before the SEC, as well as pursuing securities fraud claims against market manipulators and wrongdoers.

About Dickinson Wright PLLC
Dickinson Wright is a general practice business law firm with more than 500 attorneys among more than 40 practice areas and 16 industry groups. The firm has 23 offices in the U.S. and Canada, including Arizona, California, Colorado, Florida, Illinois, Kentucky, Michigan, Nevada, Ohio, Tennessee, Texas, Washington, and Washington, D.C. The firm's Canadian offices are located in Toronto and Windsor. Dickinson Wright has a strong securities and capital markets practice, with particular expertise in securities fraud litigation, enforcement matters, and complex commercial disputes. The firm's attorneys regularly represent public companies, underwriters, and investors in high-stakes securities litigation. The firm's Government Investigations and Securities Enforcement Practice regularly assists clients across all industries in formal and informal government investigations, enforcement proceedings, administrative actions and litigation by the SEC, PCAOB, FINRA, OTC Markets, DOJ (and US Attorney's Offices), securities exchanges, state regulators, and Congressional committees.